Drug intelligence / Profile preview

alpha-Syn100

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes, Peptides

Overview

Alpha-Syn100 is the N-terminal membrane-binding domain of alpha-synuclein. It is involved in membrane remodeling and tubulation of vesicles, a process influenced by its binding affinity and partition depth. Research has shown that a variant, NAC-null alpha-Syn100, exhibits reduced binding affinity and tubulation capacity.

Other names: N-terminal membrane-binding domain of α-synucleinα-Syn

Targets

aggregated α-syn (Alpha-synuclein (α-syn))

Beyond the preview

Go deeper on alpha-Syn100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-Syn100.

Explore the full profile